Nuvation Bio Inc. (NUVB) Stock Price

NUVBStock

$7.10+133.10%52W

Market Cap$2.49B

P/E—

PEG Ratio—

Div yield—

Beta1.59

NUVB Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)5.91%

Price vs S&P 500 (4W)-2.01%

VGM Score65.92

Book Value / Share (Quarterly)$0.73

P/TBV (Annual)10.46x

Cash Flow / Share (Quarterly)$-0.37

Price vs S&P 500 (YTD)-36.51%

Gross Margin (TTM)88.18%

Net Profit Margin (TTM)-88.19%

EPS (TTM)$-0.44

10-Day Avg Trading Volume6.32M

EPS Excl Extra (TTM)$-0.44

EPS (Annual)$-0.60

ROI (Annual)-39.81%

Gross Margin (Annual)85.22%

Cash / Share (Quarterly)$1.89

Revenue Growth QoQ (YoY)555.64%

ROA (Last FY)-34.40%

Revenue Growth TTM (YoY)1083.56%

EBITD / Share (TTM)$-0.41

ROE (5Y Avg)-45.89%

Operating Margin (TTM)-86.58%

Cash Flow / Share (Annual)$-0.52

P/B Ratio9.61x

P/B Ratio (Quarterly)7.79x

Net Income / Employee (Annual)$-686,700

EV / Revenue (TTM)15.27x

Net Interest Coverage (TTM)-24.42x

ROA (TTM)-23.49%

EPS Incl Extra (Annual)$-0.60

Current Ratio (Annual)6.95x

Quick Ratio (Quarterly)7.98x

3-Month Avg Trading Volume6.08M

52-Week Price Return133.10%

Revenue / Employee (TTM)$570,100

Tangible BV / Share (Quarterly)$0.70

P/S Ratio (Annual)38.79x

Asset Turnover (Annual)0.11x

52-Week High$9.75

EPS Excl Extra (Annual)$-0.60

CapEx CAGR (5Y)123.44%

26-Week Price Return17.16%

Quick Ratio (Annual)6.67x

13-Week Price Return41.13%

Total Debt / Equity (Annual)0.68x

Current Ratio (Quarterly)8.37x

Enterprise Value$2.59B

Asset Turnover (TTM)0.27x

Book Value / Share Growth (5Y)-2.24%

Revenue / Employee (Annual)$211,100

Pretax Margin (Annual)-325.31%

Cash / Share (Annual)$1.53

3-Month Return Std Dev64.66%

Net Income / Employee (TTM)$-502,800

ROE (Last FY)-66.93%

Net Interest Coverage (Annual)-25.65x

EPS Basic Excl Extra (Annual)$-0.60

Receivables Turnover (TTM)11.13x

Total Debt / Equity (Quarterly)1.63x

EPS Incl Extra (TTM)$-0.44

ROI (TTM)-26.73%

P/S Ratio (TTM)14.36x

Revenue / Share (Annual)$0.18

Tangible BV / Share (Annual)$0.85

Price vs S&P 500 (52W)114.79%

Year-to-Date Return-24.55%

5-Day Price Return-2.87%

EPS Normalized (Annual)$-0.60

ROA (5Y Avg)-35.67%

Net Profit Margin (Annual)-325.31%

Month-to-Date Return6.79%

Cash Flow / Share (TTM)$-0.38

EBITD / Share (Annual)$-0.62

Operating Margin (Annual)-338.72%

LT Debt / Equity (Annual)0.63x

ROI (5Y Avg)-40.14%

LT Debt / Equity (Quarterly)1.55x

EPS Basic Excl Extra (TTM)$-0.44

P/TBV (Quarterly)8.12x

P/B Ratio (Annual)10.08x

Inventory Turnover (TTM)1.96x

Pretax Margin (TTM)-88.19%

Book Value / Share (Annual)$0.88

Price vs S&P 500 (13W)38.33%

Beta1.59x

Revenue / Share (TTM)$0.49

ROE (TTM)-49.73%

52-Week Low$2.75

vGradeD

gGradeA

mGradeB

vgmGradeB

NUVB Earnings Surprise History

Q2 25-0.14est. -0.14

Q3 25-0.14est. -0.15

Q4 25-0.09est. -0.04

Q1 260.04est. 0.05

Q2 26-0.15est. -0.12

NUVB Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.12

4.13

Industry Peers — Pharmaceuticals(571)

Symbol	Value Score	Growth Score	Momentum Score	Price
NUVBNuvation Bio Inc.	D	A	B	$7.10
LLYEli Lilly & Co.	D	B	B	$1233.66
JNJJohnson & Johnson	D	C	B	$273.14
ABBVABBVIE INC.	D	C	B	$265.79
MRKMerck & Co., Inc.	D	C	A	$156.45
NVSNovartis AG	C	C	C	$159.98
AZNAstraZeneca PLC	C	B	C	$169.66
NVONovo-Nordisk A/S	B	C	C	$48.66
ABTAbbott Laboratories	C	C	B	$116.13
PFEPfizer Inc.	C	D	C	$28.57
VRTXVertex Pharmaceuticals Inc	D	C	B	$552.85
BMYBristol-Myers Squibb Co.	B	B	B	$67.92
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$46.02
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$52.07
REGNRegeneron Pharmaceuticals Inc	C	C	B	$833.56
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	C	$18.35
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$38.10
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	C	$376.37
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$62.07
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$240.08
ZTSZOETIS INC.	B	C	D	$77.29
INSMInsmed, Inc.	F	A	C	$123.89
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$36.47
UTHRUnited Therapeutics Corp	C	C	C	$518.53
GMABGenmab A/S ADS	C	C	B	$34.36
VTRSViatris Inc. Common Stock	B	C	B	$16.72
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$260.23
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$252.99
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$80.40
CORTCorcept Therapeutics Inc.	F	C	A	$123.57
BMRNBioMarin Pharmaceuticals Inc	C	C	C	$66.12
ARWRArrowhead Research Corporation	D	A	B	$88.88
ELANElanco Animal Health Incorporated Common Stock	C	B	B	$25.09
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	$512.16
CYTKCytokinetics Inc.	F	D	B	$77.46
AXSMAxsome Therapeutics, Inc	D	B	C	$205.48
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.36
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$63.57
ABVXAbivax SA American Depositary Shares	—	—	C	$117.93
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.34
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$368.02
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PTGXProtagonist Therapeutics, Inc	F	B	A	$150.59
SYRESpyre Therapeutics, Inc. Common Stock	—	—	A	$107.36
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.86
TGTXTG Therapeutics, Inc.	D	B	A	$55.42
ALKSAlkermes Inc. plc	D	C	B	$49.21
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$113.35
ORKAOruka Therapeutics, Inc. Common Stock	F	—	A	$101.82
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	$161.68
COGTCogent Biosciences, Inc. Common Stock	F	—	B	$36.80

About Nuvation Bio Inc.

Nuvation Bio is a biopharmaceutical company developing oncology treatments, with its lead candidate taletrectinib, an oral ROS1 inhibitor for patients with ROS1-positive non-small cell lung cancer. The clinical-stage pipeline includes additional oncology candidates at various development stages. Revenue is generated primarily through licensing agreements and research partnerships, with the majority coming from Japan.